Citations 2
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Konecny, Gottfried E. , Jänicke, F., Beckmann, Matthias W. , Feisel, Gabriele, Pölcher, Martin , Rody, Achim , Ray-Coquard, Isabelle Laure, Provencher, Diane , Ben‐Baruch, Noa, Cottu, Paul , Chen, Hsiao‐Wang, Dering, Judy, Jacod, Sylvie, Houé, Vincent, Slamon, Dennis J. , Haluska, Paul , Sehouli, Jalid , Roman, Lynda D. , Karlan, Beth Y. , Wang, Chen
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 5529-5529
Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).
Giordano, Heidi, Konecny, Gottfried E. , Tinker, Anna V. , Ma, Ling , Bell‐McGuinn, Katherine M., Cragun, Janiel M., Ray-Coquard, Isabelle Laure, Goble, Sandra, Maloney, Lara , McNeish, Iain A. , McNeish, Iain A , Coleman, Robert L. , Swisher, Elizabeth M. , Oza, Amit M. , Scott, Clare L. , Lin, Kevin , O’Malley, David M. , Kristeleit, Rebecca Sophie , Brenton, James D. , Oaknin, Ana , Kaufmann, Scott H.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5540-5540